![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs15033-016-0304-2/MediaObjects/15033_2016_304_Fig1_HTML.gif)
Literatur
Noth I et al., The Lancet 2013; 1: 309–17.
Fingerlin TE et al., Nat Genet 2013; 45: 613–20.
Peljto AL et al., JAMA 2013; 309: 2232–9.
Asehnoune J et al., J Immunol 2004; 172: 2522–9.
De Flora S et al., The European Respiratory Journal 1997; 10: 1535–41.
Imai Y et al., Cell 2008; 133: 235–49.
Martinez FJ et al., NEJM 2014; 370: 2093–101.
Originalie
Oldham JM, Ma SF, Martinez FJ et al. TOLLIP, MUC5B and the Response to N-acetylcysteine Among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015 15;192(12):1475–82.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Markart, P., Günther, A. Genvarianten beeinflussen das Ansprechen auf eine IPF-Therapie mit N-Acetylcystein. Pneumo News 8, 22–23 (2016). https://doi.org/10.1007/s15033-016-0304-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15033-016-0304-2